Trevi Therapeutics, Inc.

NASDAQ•TRVI

執行長: Ms. Jennifer L. Good

板塊: Healthcare

行業: Biotechnology

上市日期: 2019-05-07

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

聯絡資訊

195 Church Street, 16th Floor, New Haven, CT, 06510, United States

203-304-2499

www.trevitherapeutics.com

市值

$1.68B

本益比 (TTM)

-41.4

17.8

股息率

52周最高

$14.39

52周最低

$4.24

52周範圍

87%

排名62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

基於 9 年期基本面

疲弱 • 1.9 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2017-2025

財務儀表板

Q3 2025 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.08-38.46%

近4季度走勢

自由現金流

-$10.89M+13.98%

近4季度走勢

2025 Q3 財報亮點

核心亮點

Strong Financing Cash Inflow Net cash from financing activities totaled $120.7M, driven by June 2025 offering, boosting cash reserves to $56.9M.

Positive Phase 2b Trial Results CORAL trial met primary endpoint; 108 mg BID dose showed 60.2% reduction in 24-hour cough frequency versus placebo.

Net Loss Narrows Significantly Nine months net loss reduced to $34.4M from $36.5M, reflecting lower R&D spending compared to the prior year period.

Extended Cash Runway Forecast Total cash and marketable securities reached $193.9M, expected to fund operations and capital needs into fiscal year 2028.

關注風險

Need Substantial Future Funding Substantial expenditures expected for Phase 3 trials; failure to raise capital timely could delay or force abandonment of development.

Increased Operating Cash Burn Operating activities used $34.5M cash in nine months, up from $28.7M last year, increasing cash burn rate significantly.

Sole Product Candidate Dependency Business success relies entirely on Haduvio development, regulatory approval, and commercialization across IPF, non-IPF ILD, and RCC.

Opioid Class Label Warning Risk Active ingredient carries opioid class warning; potential for restrictive marketing or distribution regulations if applied to Haduvio.

未來展望

Key FDA Meeting Scheduled Planning End-of-Phase 2 meeting with FDA in Q4 2025; Phase 3 initiation for IPF expected in the first half of 2026.

Advance Multiple Clinical Programs Plan to initiate Phase 3 IPF trial and Phase 2b RCC trial in 2026, alongside ongoing TIDAL respiratory function study.

R&D Expenses Decreasing Nine month R&D expenses fell to $27.3M from $30.0M due to completion of several active Phase 2 clinical trials.

G&A Costs Increasing General and administrative expenses rose $2.6M for nine months, driven by personnel costs and SOX 404(b) compliance preparation.

同行對比

營業收入 (TTM)

NVAX

$1.12B

+64.7%

ARDX

$407.32M

+22.1%

SNDX

$172.35M

+627.8%

毛利率 (最新季度)

SNDX

102.3%

-13.9pp

NBTX

100.0%

+0.0pp

IMTX

100.0%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
TERN	$3.78B	-40.8	-30.0%	0.3%
WVE	$2.45B	-11.6	-85.0%	2.8%
SYRE	$2.45B	-90.5	-29.4%	0.0%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年3月17日

每股收益:-$0.10

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料